
    
      Prospectively evaluate the safety and effectiveness of CD19/CD20 dual-target CAR-T cells in
      the treatment of relapsed/refractory B-cell lymphoma . Strictly follow the inclusion criteria
      to screen eligible subjects for inclusion in clinical trials. The selected patients received
      CD19/CD20 dual-target CAR-T cell therapy. After the treatment is over, follow-up regularly to
      determine the survival status and follow-up treatment.
    
  